Last reviewed · How we verify
NCT05675033
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Phase 2 trial testing Serplulimab and Bevacizumab injection in Lung Adenocarcinoma in 50 participants. Status unknown.
10 January 2023
Quick facts
| Lead sponsor | Fujian Cancer Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 10 January 2023 |
| Primary completion | 10 January 2023 |
| Estimated completion | 10 January 2024 |
Drugs / interventions tested
- Serplulimab and Bevacizumab injection — full drug profile →
Conditions studied
- Lung Adenocarcinoma — all drugs for Lung Adenocarcinoma →
- Stage IV Non-small Cell Lung Cancer — all drugs for Stage IV Non-small Cell Lung Cancer →
- PD-1 Inhibitor — all drugs for PD-1 Inhibitor →
- VEGF — all drugs for VEGF →
Sponsor
Fujian Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Lung Adenocarcinoma or Stage IV Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to further evaluate the efficacy of immunotherapy combined with antivascular therapy in the real world, we used Serpluimab combined with Bevacizumab and platinum-based chemotherapy in previously untreated EGFR/ALK-negative advanced non-squamous NSCLC patients, to evaluate the efficacy and safety of this regimen.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Molecular and Cellular Machinery of Lymphatic Metastasis in Breast Cancer.
Cong B, Cao X, Jiang WG, Ye L. · · 2025 · cited 5× · PMID 39926374 · DOI 10.2147/ott.s503272 -
Tumor-Associated Macrophages as Therapeutic Targets: Deciphering Interaction Networks and Advancing Clinical Translation.
Bao W, Qu X, Wang Y, Huang D, et al · · 2026 · PMID 41614207 · DOI 10.1002/mco2.70599
Verify or expand the search:
- PubMed search for NCT05675033
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Adenocarcinoma
Currently open trials in the same condition.
- NCT07481786 — Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases · Phase 3 · recruiting
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT07235280 — Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma · EARLY_PHASE1 · recruiting
- NCT07161713 — SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors · NA · recruiting
- NCT07479095 — Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic · NA · recruiting
Other Fujian Cancer Hospital trials
Trials by the same sponsor.
- NCT07470840 — SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma · Phase 2 · not yet recruiting
- NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07492654 — Clinical Study on the Prevention and Treatment of Radiation Vaginitis With Triethanolamine Cream · Phase 4 · not yet recruiting
- NCT07399158 — CROSSROAD: Treatment Regimen Switch - Re-induction Chemotherapy vs. Direct Radiotherapy in LANPC With Inadequate Respons · not yet recruiting
- NCT07256236 — SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05675033 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fujian Cancer Hospital
- Last refreshed: 9 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05675033.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing